电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Recombinant FOLR1 (Mirvetuximab Biosimilar) 抗体

This 小鼠 单克隆 anti-FOLR1 (Mirvetuximab Biosimilar) antibody specifically detects FOLR1 (Mirvetuximab Biosimilar) in FACS 和 in vivo. The antibody is reactive with 人 samples.
产品编号 ABIN7795120
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for Recombinant FOLR1 (Mirvetuximab Biosimilar) 抗体 (ABIN7795120)

抗原

FOLR1 (Mirvetuximab Biosimilar)

抗体类型

Recombinant Antibody

适用

宿主

  • 2
  • 1
  • 1
小鼠

克隆类型

  • 3
  • 1
单克隆

标记

  • 4
This FOLR1 (Mirvetuximab Biosimilar) antibody is un-conjugated

应用范围

  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

质量等级

Research Grade
  • Expression System

    Mammalian cells

    原理

    Mirvetuximab Biosimilar, Human FOLR1 Monoclonal Antibody

    产品特性

    What is Mirvetuximab biosimilar research grade? Mirvetuximab biosimilar uses the same protein sequences as the therapeutic antibody Mirvetuximab. Mirvetuximab soravtansine is used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha (FRa)-directed antibody and microtubule inhibitor conjugate.

    纯化方法

    Protein A or G affinity column

    纯度

    >95 % by reducing SDS-PAGE

    内毒素水平

    < 1 EU per 1 mg of the protein by the LAL method

    免疫原

    Human FOLR1
  • 应用备注

    Optimal working dilution should be determined by the investigator.

    限制

    仅限研究用
  • 状态

    Liquid

    浓度

    > 3 mg/mL

    储存条件

    4 °C,-20 °C

    储存方法

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • 抗原

    FOLR1 (Mirvetuximab Biosimilar)

    别名

    Mirvetuximab Biosimilar

    物质类

    Biosimilar
You are here: